Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study.

Mathias Due Buron Tomas KalincikFinn SellebjergPer Soelberg SørensenMelinda Magyari

Published in: Journal of neurology, neurosurgery, and psychiatry (2021)

Switching from injectable platform therapies to oral first-line therapies in patients with clinically stable RRMS does not increase the risk of disability accumulation. While the postswitch risk of relapses trended towards marginally higher on TFL, this trend was eliminated by adjustment for time-variant confounders.

Keyphrases

multiple sclerosis
white matter
minimally invasive
high intensity
high throughput
stem cells
hyaluronic acid
cell therapy